Alternate-Day Buprenorphine Administration. Phase II - 4

This study has been completed.

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) University of Vermont
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000222

Purpose

The purpose of this study is to determine if two times a subject's daily maintenance dose will hold for 48 hours without changes in agonist and antagonist effects.

Condition	Intervention	Phase
Opioid-Related Disorders	Drug: Buprenorphine	Phase I

Drug Information available for: Buprenorphine Buprenorphine hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Placebo Control, Crossover Assignment
Official Title:	Alternate-Day Buprenorphine Administration. Phase II

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Drug use
Opioid withdrawal
Opioid agonist effects
Dose identification
Pupil diameter

Estimated Enrollment:	0
Study Start Date:	July 1992

Eligibility

Ages Eligible for Study:	28 Years to 45 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000222

Locations

United States, Vermont
Treatment Research Center
Burlington, Vermont, United States, 05401

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

University of Vermont

Investigators

Principal Investigator:

Warren Bickel, Ph.D.

University of Vermont

More Information

Study ID Numbers:	NIDA-06969-4, R01-06969-4
Study First Received:	September 20, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000222
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Buprenorphine
Mental Disorders
Substance-Related Disorders
Disorders of Environmental Origin
Opioid-Related Disorders

Additional relevant MeSH terms:

Sensory System Agents
Therapeutic Uses
Narcotic Antagonists
Physiological Effects of Drugs
Central Nervous System Depressants
Narcotics

Peripheral Nervous System Agents
Analgesics
Central Nervous System Agents
Pharmacologic Actions
Analgesics, Opioid

ClinicalTrials.gov processed this record on January 15, 2009